Angiogenesis using placental stem cells

Patent metadata

Field	Value
Publication number	US-2016106784-A1
Application number	US-201514978723-A
Country	US
Kind code	A1
Filing date	Dec 22, 2015
Priority date	Apr 7, 2010
Publication date	Apr 21, 2016
Grant date	—

Abstract

Provided herein are methods of treating individuals having diseases or disorders of the circulatory system, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein, and populations of such placental cells. The invention also provides methods of angiogenesis using such cells or populations of cells comprising such cells.

First claim

What is claimed:

1 . An isolated placental derived adherent cell, wherein said cell is adherent to tissue culture plastic, and wherein said cell is CD10 + , CD34 − , CD105 + and CD200 + as determined by flow cytometry, and wherein said cell (1) promotes the proliferation of endothelial cells; (2) promotes the formation of sprouts or tube-like structures in a population of endothelial cells; or (3) promote the migration of endothelial cells.

2 . The isolated cell of claim 1 , wherein said cell is CD45 − and CD90 + , as determined by flow cytometry.

3 . The isolated cell of claim 1 , wherein said cells express one or more of VEGF, HGF, IL-8, MCP-3, FGF2, follistatin, G-CSF, EGF, ENA-78, GRO, IL-6, MCP-1, PDGF-BB, TIMP-2, uPAR, or galectin-1 as determined by antibody binding.

4 . An isolated population of cells comprising the cell of claim 1 .

5 . The isolated population of cells of claim 4 , wherein at least 50% of the cells in said population are the cells of claim 1 .

6 . The isolated population of cells of claim 4 , wherein at least 90% of the cells in said population are the cells of claim 1 .

7 . The isolated population of cells of claim 7 , wherein at least 50% of the cells in said population are the cells of claim 1 .

8 . The isolated population of cells of claim 1 , wherein at least 90% of the cells in said population are the cells of claim 1 .

9 . A composition comprising the isolated placental derived adherent cell of claim 1 .

10 . The isolated population of claim 4 comprising a second type of cell.

11 . The isolated population of cells of claim 10 , wherein said second type of cell is an embryonic stem cell, a blood cell, a stem cell isolated from peripheral blood, a stem cell isolated from placental blood, a stem cell isolated from umbilical cord blood, an umbilical cord stem cell, a bone marrow-derived mesenchymal stem cell, a bone marrow-derived mesenchymal stromal cell, a hematopoietic stem cell, a somatic stem cell, a chondrocyte, a fibroblast, a muscle cells, an endothelial cell, an angioblast, an endothelial progenitor cell, a pericyte, a cardiomyocyte, a myocyte, a cardiomyoblast, a myoblast, an embryonic stem cell, or a cell manipulated to resemble an embryonic stem cell.

12 . The isolated population of cells of claim 11 , wherein said second type of cell comprises at least 10% of cells in said population.

13 . The isolated population of cells of claim 11 , wherein said second type of cell comprises at least 25% of cells in said population.

14 . The isolated population of cells of claim 11 , wherein said second type of cell is a hematopoietic stem or progenitor cell.

15 . The isolated population of claim 14 , wherein said hematopoietic stem or progenitor cell is a CD34 + cell.

16 . A permanent or degradable decellularized or synthetic matrix or scaffold comprising the cell of claim 1 .

17 . The matrix or scaffold of claim 16 , wherein said matrix or scaffold is an amniotic membrane; a dehydrated extracellular matrix; placental collagen, or placental extracellular membrane.

18 . A method of treating an individual having a disease or disorder of the circulatory system, comprising administering a population of the cells of claim 1 to said individual in an amount and for a time sufficient for detectable improvement of one or more symptoms of said disease or disorder.

19 . A method of treating an individual having a disease or disorder of the circulatory system, comprising administering a population of the cells of claim 1 to said individual in an amount and for a time sufficient for detectable improvement of one or more indicia of cardiac function, wherein said indicia of cardiac function are chest cardiac output (CO), cardiac index (CI), pulmonary artery wedge pressure (PAWP), cardiac index (CI), % fractional shortening (% FS), ejection fraction (EF), left ventricular ejection fraction (LVEF); left ventricular end diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD), contractility (dP/dt), a decrease in atrial or ventricular functioning, an increase in pumping efficiency, a decrease in the rate of loss of pumping efficiency, a decrease in loss of hemodynamic functioning, or decrease in complications associated with cardiomyopathy, as compared to the individual prior to administration of placental derived adherent cells.

20 . A method of treating an individual having a disruption of blood flow in or around a limb, comprising administering a therapeutically effective amount of the placental derived adherent cells of claim 1 .

Assignees

• Anthrogenesis Corp

Inventors

• Abbot Stewart
• Edinger James W
• Francki Aleksandar
• Hariri Robert J
• Jankovic Vladimir
• Kaplunovsky Aleksandr
• Labazzo Kristen
• Law Eric
• Padliya Neerav D
• Paredes Jennifer
• Wang Jia-Lun

Classifications

• A61P9/12

  Antihypertensives · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P9/06

  Antiarrhythmics · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title